-+ 0.00%
-+ 0.00%
-+ 0.00%

NervGen Q3 Net Loss Widens 36% to C$ 6.4 Million

PUBT·11/16/2026 12:21:01
Listen to the news
NervGen Q3 Net Loss Widens 36% to C$ 6.4 Million
  • NervGen’s third-quarter 2026 net loss widened 36% year over year to CAD 6.4 million.
  • R&D expenses rose 84% to CAD 7.9 million; G&A expenses more than doubled to CAD 3.3 million year over year.
  • Cash totaled CAD 80.1 million at September 30, 2026, expected to fund operations through RESTORE’s anticipated first-half 2028 topline readout.
  • Phase 3 RESTORE enrollment remains ongoing, with completion expected in the second half of 2027.
  • Following NVG-291’s FDA Breakthrough Therapy designation, management plans to request a multidisciplinary Type B meeting to discuss development and opportunities to expedite the program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NervGen Pharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160715PRIMZONEFULLFEED9878020) on November 16, 2026, and is solely responsible for the information contained therein.